Cemiplimab-RWLC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cemiplimab-RWLC Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
223
Registered trials
256
Result records
11
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cemiplimab-RWLC can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cemiplimab-RWLC (query alias: cemiplimab) |
|---|---|
| Modality / target | Monoclonal antibody; PD-1; PD-1 inhibitors |
| Highest global status | Approved |
| Originator | Regeneron Pharmaceuticals, Inc. |
| Active developers | Regeneron Pharmaceuticals, Inc., Sanofi (China) Investment Co. Ltd., Sanofi |
The MCP disease footprint includes Metastatic Carcinoma to the Uterine Cervix, Advanced Cervical Carcinoma, Recurrent Cervical Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07620548 | Phase 2 | Not yet recruiting | 99 | Progression-free survival (PFS) at Month 6 (PFS6) |
| NCT07594106 | Phase 1/2 | Not yet recruiting | 265 | Occurrence of Dose Limiting Toxicities (DLTs) |
| NCT07567469 | Phase 1/2 | Not yet recruiting | 120 | Occurrence of Treatment Emergent Adverse Events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease
Phase 2; n=148; evaluation: Positive. Reported fields: TRAE(grade 5) = 5.0 %
A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer
Phase 3; n=712; evaluation: not stated. Reported fields: OS(Median) = 13.7 months (95% Confidence Interval, 11.2 - 16.2); OS(Median): Hazard Ratio (HR) = 0.661(95% CI, 0.553 - 0.790), P-Value = <0.0001; OS(Median): Hazard Ratio (HR) = 0.661(95% CI, 0.553 - 0.790), P-Value = <0.0001
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
Phase 1/2; n=95; evaluation: not stated. Reported fields: Grade 3 or greater AEs = 12 Participants ; Grade 3 or greater AEs = 7 Participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cemiplimab-RWLC addresses Metastatic Carcinoma to the Uterine Cervix, Advanced Cervical Carcinoma, Recurrent Cervical Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-12-28 | Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets | Approved | Financial terms not disclosed |
| 2024-03-01 | GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta | Approved | Financial terms not disclosed |
| 2024-01-08 | Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination therapies using CDK4 inhibitors with PD-1 axis binding antagonists”. The milestone feed surfaced a patent-application signal described as “Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer”. The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with PD1/PD-l1 inhibitors”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
